Fig. 3From: Clinical features and biomarkers of semantic variant primary progressive aphasia with MAPT mutationPlasma NfL and GFAP concentrations in mutation carriers and noncarriers. There was no difference in A NfL or B GFAP between 9 mutation carriers and 9 noncarriers, although the levels of NfL and GFAP were higher in the two patients designated III-12 and IV-22 (indicated by the dashed boxes) than in presymptomatic carriers or noncarriersBack to article page